Corcept Therapeutics CORT
$63.62 −$1.36 (-2.09%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $63.62 0.00%
Open$64.07
Prev close$64.98
Day range$62.81 – $65.13
Volume1.09M
Market cap$6.96B
P/E (TTM)47.8
Dividend yield–
CORT Stock News
Headlines matching Corcept Therapeutics or the CORT ticker, most recent first.
- H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
- Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks
- Corcept Therapeutics(CORT.US) Officer Sells US$3.89 Million in Common Stock
- Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
- Corcept Therapeutics(CORT.US) Director Sells US$12.25 Million in Common Stock
- Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164
- CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $161
- CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135
- H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165 Positive
- Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165 Positive
- Wolfe Research Maintains Corcept Therapeutics(CORT.US) With Sell Rating, Maintains Target Price $50
- CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $161 Positive
- Wolfe Research Downgrades Corcept Therapeutics(CORT.US) to Sell Rating, Announces Target Price $50 Negative
- H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $95
- Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88
No comments yet — be the first to weigh in on CORT.
Sign in to join the discussion.